SEC Comment Letter 0000000000-24-011695 to Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc.
Date: Oct. 17, 2024 · CIK: 0001642380 · Accession: 0000000000-24-011695
AI Filing Summary & Sentiment
File numbers found in text: 333-282683
Letter
October 17, 2024 Joshua Riggs President and Chief Executive Officer Oncocyte Corporation 15 Cushing Irvine, California 92618 Re:Oncocyte Corporation Registration Statement on Form S-3 Filed October 16, 2024 File No. 333-282683 Dear Joshua Riggs: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Alok A. Choksi, Esq.
Show Raw Text
October 17, 2024
Joshua Riggs
President and Chief Executive Officer
Oncocyte Corporation
15 Cushing
Irvine, California 92618
Re:Oncocyte Corporation
Registration Statement on Form S-3
Filed October 16, 2024
File No. 333-282683
Dear Joshua Riggs:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Alok A. Choksi, Esq.